Organogenesis (ORGO) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Organogenesis (ORGO) over the past year, losing 46.2% versus a loss of 75.3%. Over five years, TLSA leads with a -30.5% price change compared with -90.6% for ORGO. Tiziana Life Sciences is the larger company by market cap ($133.6 million vs $128.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORGO | TLSA |
|---|---|---|
| Share price | $0.9997 | $1.05 |
| Market cap | $128.64M | $133.62M |
| 1-day change | -9.94% | 0.00% |
| YTD return | -80.70% | -29.53% |
| 1-year return | -75.25% | -46.15% |
| 5-year return | -90.57% | -30.46% |
| EPS (TTM) | $-0.83 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $564.17M | — |
| Revenue growth (YoY) | +17.04% | — |
| Net income (latest FY) | $37.03M | $-11.86M |
| Operating margin | 7.92% | — |
| Net margin | 6.56% | — |
| 52-week high | $7.08 | $2.10 |
| 52-week low | $0.99 | $0.76 |
| Distance from 52-week high | -85.87% | -50.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +100.06% | +667.62% |
| Average volume | 757.06K | 764.91K |
| Shares outstanding | 128.67M | 127.26M |
| Employees | 854 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed ORGO by 29.1 percentage points over the past year.
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ORGO vs TLSA FAQ
Which is bigger, Organogenesis or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $133.62M compared with $128.64M for Organogenesis (ORGO).
Which stock has performed better over the past year, ORGO or TLSA?
TLSA returned -46.15% over the past 12 months, compared with -75.25% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Organogenesis and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.